# Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

> **NCT03400943** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 93 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03400943
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-17
- **Primary completion:** 2019-06-09
- **Final completion:** 2022-04-06
- **Target enrollment:** 93 (ACTUAL)
- **Why stopped:** Due to a change in the development program, the study was closed prematurely.
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400943, "Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03400943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*